CD274 and melanoma: The long-term efficacy of ICB, which targets Programmed Death-1 (PD-1) and its ligand PD-L1, has been confirmed in various randomized phase III clinical trials involving patients with melanoma, NSCLC, and renal cell carcinoma (RCC), among others [6,7,8].